Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Cystinosis
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Cystinosis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Cystinosis (Mendelian lysosomal storage disorder): Comprehensive disease characteristics report (evidence-focused)

Executive summary

Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by biallelic CTNS pathogenic variants leading to deficient lysosomal cystine export (cystinosin dysfunction) and intracellular/lysosomal cystine accumulation with crystal formation, producing early renal Fanconi syndrome and progressive multi‑organ disease (notably eye, endocrine organs, muscle, GI system). (devitt2024cystinosis—a pages 1-2, bondue2024novelmolecularmechanisms pages 20-23, cherqui2023[cystinosisfromthe pages 1-3)

A rapid-reference table of the highest-yield facts extracted from the evidence is provided here:

Table: This table condenses the most actionable cystinosis facts from the gathered evidence, including identifiers, epidemiology, phenotypes, diagnostics, standard care, real-world access/adherence data, and emerging therapies. It is useful as a rapid reference for populating a disease knowledge base entry.

A key visual summary of global disparities in access to testing and cysteamine therapy is available in the extracted table image. (regnier2024worldwidedisparitiesin media 96f6e599)

1. Disease information

1.1 Definition/overview (current understanding)

• Cystinosis is described as a rare autosomal recessive lysosomal storage disorder characterized by lysosomal cystine accumulation due to CTNS/cystinosin dysfunction, causing cellular dysfunction and multi-organ damage. (devitt2024cystinosis—a pages 1-2, bondue2024novelmolecularmechanisms pages 20-23)
• A recent review states: “Cystinosis is a rare autosomal recessive disease characterised by an accumulation of cystine in the lysosomes… caused by pathogenic variants of the cystinosin gene (CTNS).” (devitt2024cystinosis—a pages 1-2)

1.2 Key identifiers (as available from tool-retrieved evidence)

• MONDO: MONDO_0016239 (“cystinosis”) appears as the disease identifier in Open Targets disease-target association data. (Open Targets tool output; MONDO ID itself is not reprinted in an evidence snippet, so it is not additionally citable beyond that tool-derived context.)
• MeSH: ClinicalTrials.gov lists Cystinosis MeSH ID: D003554. (NCT01197378 chunk 2)

Not available in retrieved evidence excerpts: OMIM, Orphanet, ICD‑10/ICD‑11 codes were not explicitly provided in the texts successfully retrieved and evidence-scanned here; these will require direct lookup in OMIM/Orphanet/ICD resources outside the current evidence set.

1.3 Synonyms/alternative names (from retrieved sources)

• Nephropathic cystinosis; infantile nephropathic cystinosis; juvenile/intermediate nephropathic cystinosis; ocular (non‑nephropathic) cystinosis. (bondue2024novelmolecularmechanisms pages 20-23, devitt2024ocularcystinosis–areview pages 1-2, dong2023thegenetherapy pages 1-3)

1.4 Evidence source types represented here

• Aggregated disease-level resources: ClinicalTrials.gov metadata (MeSH mapping; trial protocol descriptions), and an international survey of treatment/testing access. (NCT01197378 chunk 2, regnier2024worldwidedisparitiesin pages 1-2)
• Peer-reviewed reviews, clinical perspectives, cohort/case series, and preclinical model studies. (devitt2024cystinosis—a pages 1-2, joseph2024gastrointestinalchallengesin pages 1-2, algasem2024adherencetocysteamine pages 1-2, dong2023thegenetherapy pages 1-3)

2. Etiology

2.1 Disease causal factors

• Genetic cause: Pathogenic variants in CTNS (cystinosin) disrupt lysosomal cystine export (cystine-H+ cotransporter), causing intralysosomal cystine accumulation and cystine crystal formation. (bondue2024novelmolecularmechanisms pages 20-23, devitt2024cystinosis—a pages 1-2, cherqui2023[cystinosisfromthe pages 1-3)
• Variant spectrum: Reviews summarize >140–160 CTNS pathogenic variants and highlight a recurrent 57-kb deletion enriched in North America/Northern Europe (reported as 50–70% of cases in one ocular review and ~75% of alleles in Northern Europe in one review). (devitt2024ocularcystinosis–areview pages 1-2, bondue2024novelmolecularmechanisms pages 20-23, devitt2024cystinosis—a pages 1-2)

2.2 Risk factors

• Primary risk is inheritance of biallelic CTNS pathogenic variants (autosomal recessive). (devitt2024cystinosis—a pages 1-2, cherqui2023[cystinosisfromthe pages 1-3)
• Founder effects are implied by high regional frequencies (e.g., Quebec, Brittany) and recurrent variants/deletions reported in reviews. (devitt2024cystinosis—a pages 1-2)

2.3 Protective factors / gene–environment interactions

• No protective genetic variants or specific gene–environment interactions were explicitly described in the retrieved evidence excerpts.

3. Phenotypes (clinical manifestations)

3.1 Core renal phenotype

• Infantile/nephropathic cystinosis typically presents with renal Fanconi syndrome (proximal tubular dysfunction) starting in infancy (reported ~6–12 months), including polyuria, electrolyte losses, acidosis, phosphaturia, glycosuria, proteinuria, and growth retardation/rickets. (bondue2024novelmolecularmechanisms pages 20-23, dong2023thegenetherapy pages 1-3, cherqui2023[cystinosisfromthe pages 1-3)

Suggested HPO terms (examples): - Renal Fanconi syndrome (HP:0001994), Polydipsia (HP:0001959), Metabolic acidosis (HP:0001942), Hyperphosphaturia (HP:0003109), Glycosuria (HP:0003076), Aminoaciduria (HP:0003355), Rickets (HP:0002748), Growth delay (HP:0001510).

3.2 Ocular phenotype

• Corneal cystine crystals are described as pathognomonic, with diagnosis “primarily made using slit lamp examination.” (devitt2024ocularcystinosis–areview pages 1-2)
• A case series describes crystals as “needle‑shaped refractile opacities” and notes they can be evident by ~16 months, with photophobia. (heroor2024unveilingcystinosisin pages 9-11)

Suggested HPO terms: Photophobia (HP:0000613), Corneal opacity (HP:0007957).

3.3 Extra-renal phenotypes (endocrine, muscle, GI, neurologic)

• Reviews and clinical perspectives summarize multi-organ disease including hypothyroidism, diabetes, hypogonadism, myopathy, and swallowing/respiratory complications. (devitt2024cystinosis—a pages 1-2, cherqui2023[cystinosisfromthe pages 1-3, joseph2024gastrointestinalchallengesin pages 7-9)
• GI sequelae are described as “nearly universal” and occur “at virtually every disease stage,” with survey-based symptom frequencies including swallowing difficulties (54%), nausea (38%), loss of appetite (21%), diarrhea (19%), and vomiting (15%). (joseph2024gastrointestinalchallengesin pages 1-2)

Suggested HPO terms: Hypothyroidism (HP:0000821), Diabetes mellitus (HP:0000819), Hypogonadism (HP:0000135), Dysphagia (HP:0002015), Nausea (HP:0002018), Diarrhea (HP:0002014), Vomiting (HP:0002013).

3.4 Quality-of-life impact

• A 2024 prospective cohort from Saudi Arabia found QoL deficits on SF‑36, with the lowest domain means in social functioning and energy/fatigue. (algasem2024adherencetocysteamine pages 1-2, algasem2024adherencetocysteamine pages 6-7)

4. Genetic / molecular information

4.1 Causal gene

• CTNS encodes cystinosin, a lysosomal cystine–proton cotransporter; loss of function causes lysosomal cystine accumulation. (cherqui2023[cystinosisfromthe pages 1-3, bondue2024novelmolecularmechanisms pages 20-23)

4.2 Pathogenic variant types / notable alleles

• Reviews cite numerous pathogenic variants (>140–160) and population-enriched large deletions (57 kb). (devitt2024cystinosis—a pages 1-2, bondue2024novelmolecularmechanisms pages 20-23, devitt2024ocularcystinosis–areview pages 1-2)

4.3 Modifier genes / epigenetic information

• The retrieved evidence set does not provide a validated modifier-gene catalogue or epigenetic mechanisms specific to cystinosis.

5. Environmental information

Cystinosis is primarily genetic; the retrieved sources do not describe established environmental triggers or protective exposures.

6. Mechanism / pathophysiology

6.1 Primary molecular defect → cellular dysfunction → organ disease (causal chain)

• Upstream: Biallelic CTNS loss-of-function → cystinosin deficiency in lysosomal membrane. (bondue2024novelmolecularmechanisms pages 20-23, cherqui2023[cystinosisfromthe pages 1-3)
• Core biochemical consequence: failure of cystine export → intra-lysosomal cystine accumulation and crystal formation. (bondue2024novelmolecularmechanisms pages 20-23, cherqui2023[cystinosisfromthe pages 1-3)
• Downstream (organ level): early proximal tubule dysfunction (Fanconi syndrome) → progression to chronic kidney disease/ESKD; systemic cystine/crystal effects in eye/endocrine/muscle/GI, etc. (bondue2024novelmolecularmechanisms pages 20-23, cherqui2023[cystinosisfromthe pages 1-3, joseph2024gastrointestinalchallengesin pages 1-2)

6.2 Key pathways and cellular processes (from retrieved sources)

• Cysteamine is described mechanistically as reacting 1:1 with cystine to form products that can exit lysosomes; this reduces cystine but does not fully prevent later complications. (simeoli2024anewand pages 1-2)
• Reviews also discuss downstream cellular dysfunction and note adjunct mechanistic approaches (e.g., TFEB activation; mTOR inhibition) as therapeutic concepts. (bondue2024novelmolecularmechanisms pages 20-23)

Suggested GO biological process terms (examples): lysosomal transport; cystine transport; autophagy; cellular response to oxidative stress. (GO IDs not provided in retrieved evidence; suggested conceptually.)

Suggested CL cell types (examples): kidney proximal tubule epithelial cell; podocyte; corneal epithelial cell; macrophage/monocyte (tissue crystals in macrophages are discussed in GI tissue studies). (joseph2024gastrointestinalchallengesin pages 1-2, joseph2024gastrointestinalchallengesin pages 4-6)

7. Anatomical structures affected

• Primary organ/system: kidney (proximal tubule; Fanconi syndrome; ESKD). (bondue2024novelmolecularmechanisms pages 20-23, cherqui2023[cystinosisfromthe pages 1-3)
• Common extra-renal: cornea/eye; endocrine organs (thyroid, pancreas/gonads); skeletal muscle; GI tract and hepatosplenic involvement. (devitt2024cystinosis—a pages 1-2, joseph2024gastrointestinalchallengesin pages 1-2, joseph2024gastrointestinalchallengesin pages 11-13)

Suggested UBERON terms (examples): kidney; proximal tubule; cornea; thyroid gland; pancreas; skeletal muscle; gastrointestinal tract; liver; spleen.

Suggested GO cellular component: lysosome.

8. Temporal development

• Onset: infantile nephropathic cystinosis often starts in infancy (~6–12 months) with Fanconi syndrome. (bondue2024novelmolecularmechanisms pages 20-23, cherqui2023[cystinosisfromthe pages 1-3)
• Progression: without treatment, progression to ESKD is described within the first decade; a review states “90%” progress to kidney failure within 20 years. (dong2023thegenetherapy pages 1-3, devitt2024cystinosis—a pages 1-2)

9. Inheritance and population

9.1 Inheritance

• Autosomal recessive inheritance is consistently stated. (devitt2024cystinosis—a pages 1-2, cherqui2023[cystinosisfromthe pages 1-3)

9.2 Epidemiology statistics

• Incidence estimates in recent sources include 0.5–1 per 100,000 live births and ~1:100,000–1:200,000 births, with higher regional frequencies reported in Quebec and Brittany. (devitt2024cystinosis—a pages 1-2, simeoli2024anewand pages 1-2, cherqui2023[cystinosisfromthe pages 1-3)

9.3 Health-system/real-world implementation disparities (2023 perspective; published 2024)

An international cross-sectional survey (109 centers/49 countries; 741 patients) quantified major inequities: - Genetic testing availability: 63% in developing/economies-in-transition vs 100% in developed economies. (regnier2024worldwidedisparitiesin pages 1-2, regnier2024worldwidedisparitiesin pages 2-3) - Intra-leukocyte cystine (IL‑CL) availability: 30% vs 94–95%. (regnier2024worldwidedisparitiesin pages 1-2, regnier2024worldwidedisparitiesin pages 2-3) - Delayed-release cysteamine availability: 7% vs 74%. (regnier2024worldwidedisparitiesin pages 1-2, regnier2024worldwidedisparitiesin pages 2-3) - Cysteamine eye drops availability: 63% vs 95%. (regnier2024worldwidedisparitiesin pages 2-3)

A table image extracted from the paper summarizes these access gaps by country grouping. (regnier2024worldwidedisparitiesin media 96f6e599)

10. Diagnostics

10.1 Core tests/biomarkers

• Leukocyte (PMN/granulocyte) cystine is a key diagnostic/monitoring biomarker; one review reports thresholds: <0.20 (healthy), <1.00 (heterozygote), >3.00 (nephropathic cystinosis). (bondue2024novelmolecularmechanisms pages 20-23)
• Ophthalmic slit-lamp examination for corneal crystals is a primary diagnostic approach for ocular involvement; corneal crystals are described as pathognomonic. (devitt2024ocularcystinosis–areview pages 1-2, heroor2024unveilingcystinosisin pages 9-11)
• Genetic testing (CTNS) is part of diagnostic confirmation and is also the basis for newborn screening pilots using dried blood spots. (bondue2024novelmolecularmechanisms pages 20-23, NCT06027385 chunk 2)

10.2 Screening

• Two German “GENESIS” molecular newborn screening pilots are documented on ClinicalTrials.gov:
• NCT06027385 (GENESIS1): completed; dried blood spot at 36–72 h; first-tier multiplex PCR for 3 CTNS mutations with reflex NGS; actual enrollment 300,000. (NCT06027385 chunk 1, NCT06027385 chunk 2)
• NCT05843851: recruiting; planned screening 200,000 newborns; PCR for common CTNS mutations with reflex amplicon-based NGS for pathogenic CTNS variants; start 2022‑03‑15. (NCT05843851 chunk 1, NCT05843851 chunk 2)

10.3 Differential diagnosis

A formal differential diagnosis list was not explicitly provided in the retrieved excerpts; clinically, early Fanconi syndrome prompts evaluation for other causes of proximal tubular dysfunction (not detailed in this evidence set).

11. Outcome / prognosis

• Progression to kidney failure/ESKD remains a major outcome: one review reports “90% of cystinosis patients progress to kidney failure within the first 20 years of life” and notes kidney transplantation as the option at that stage. (devitt2024cystinosis—a pages 1-2)
• GI and swallowing complications can contribute to morbidity and mortality: one clinical perspective reports that in a cohort, “5 of 33 deaths were attributed to a combination of respiratory and swallowing complications.” (joseph2024gastrointestinalchallengesin pages 7-9)

12. Treatment

12.1 Pharmacotherapy (standard of care)

• Cysteamine bitartrate is the disease-specific cystine-depleting therapy; a 2024 methods paper states it is approved for children and adults and that it improved prognosis, but does not fully prevent progression/complications and has frequent side effects. (simeoli2024anewand pages 1-2)
• Immediate-release (IR) vs delayed-release (DR) cysteamine: IR is commonly dosed q6h (four times/day) and DR q12h (twice/day); a cohort paper provides dosing examples and lists common adverse effects and adherence challenges. (algasem2024adherencetocysteamine pages 1-2)
• Topical cysteamine is used for corneal crystals because oral therapy does not reach the avascular cornea; one cohort describes hourly dosing while awake for CYSTARAN®. (algasem2024adherencetocysteamine pages 1-2)

Suggested MAXO terms (examples): cystine-depleting therapy; oral pharmacotherapy; topical ophthalmic therapy; kidney transplantation; electrolyte supplementation; nutritional support.

12.2 Supportive and multidisciplinary management (real-world implementation)

• A 2024 GI-focused clinical perspective emphasizes that GI sequelae are nearly universal and recommends proactive symptom monitoring, multidisciplinary management, and medication strategies to improve tolerability and adherence. (joseph2024gastrointestinalchallengesin pages 1-2, joseph2024gastrointestinalchallengesin pages 9-10)

12.3 Emerging/experimental therapies (pipeline)

• Hematopoietic stem cell (HSPC) gene therapy: ClinicalTrials.gov trial NCT03897361 (Phase 1/2; status completed) evaluates autologous CD34+ cells transduced ex vivo with lentiviral vectors expressing CTNS, with primary outcomes focused on safety/tolerability and secondary measures including leukocyte/granulocyte cystine, eGFR, thyroid labs, and vector copy number through 24 months with long-term follow-up offered. (NCT03897361 chunk 1, NCT03897361 chunk 2, NCT03897361 chunk 3)
• Ocular AAV gene therapy (preclinical): A 2023 mouse study reports experimental scAAV‑CTNS treatment reducing corneal crystal pathology in CRISPR-engineered nonsense cystinosis mouse lines. (dong2023thegenetherapy pages 1-3)

13. Prevention

• Primary prevention: not applicable in the usual sense for an autosomal recessive monogenic disease.
• Secondary prevention (earlier detection): molecular newborn screening pilots aim to enable earlier diagnosis and earlier initiation of cystine-depleting therapy to improve prognosis (ClinicalTrials.gov GENESIS programs). (NCT06027385 chunk 1, NCT05843851 chunk 1)

14. Other species / natural disease

The retrieved evidence set includes preclinical models but did not document naturally occurring cystinosis in companion animals or other species.

15. Model organisms

• Mouse models: A 2023 ocular-surface study generated CRISPR-engineered nonsense cystinosis mouse lines and used them to evaluate ocular gene therapy (scAAV-CTNS) effects on corneal crystal phenotype. (PMID:37355021; dong2023thegenetherapy pages 1-3)

Recent developments (2023–2024 emphasis) and expert analysis

1. Global implementation and access: A 2024 international survey provides quantitative evidence that disparities in access to genetic testing, leukocyte cystine monitoring, and delayed‑release cysteamine remain substantial between developing and developed economies, despite improvements over the last decade—important for real-world outcomes and equitable care. (regnier2024worldwidedisparitiesin pages 2-3, regnier2024worldwidedisparitiesin pages 1-2, regnier2024worldwidedisparitiesin media 96f6e599)
2. Symptom burden beyond the kidney: A 2024 clinical perspective reframes GI morbidity as nearly universal and potentially modifiable with proactive multidisciplinary management; it also calls out evidence gaps and prioritizes future studies in GI care pathways. (joseph2024gastrointestinalchallengesin pages 1-2, joseph2024gastrointestinalchallengesin pages 13-14)
3. Translation to disease-modifying therapies: Stem-cell gene therapy has progressed to a completed Phase 1/2 ClinicalTrials.gov study with long-term follow-up plans; ocular gene therapy has supportive preclinical evidence in mouse models. (NCT03897361 chunk 1, dong2023thegenetherapy pages 1-3)

Evidence gaps / limitations of this report

• Many retrieved review/case-series excerpts did not include PMIDs in the available text; therefore, PMID-preferred citation could not be consistently provided from the tool-accessed evidence, even when the underlying articles likely have PubMed records. Key claims are nevertheless tied to the evidence snippets above.
• OMIM/Orphanet/ICD codes were not explicitly stated in the retrieved evidence excerpts and should be added by direct database lookup.

URLs and publication dates (from evidence)

• Devitt L. Cystinosis — a review… (Jun 2024). https://doi.org/10.1007/s44162-024-00041-2 (devitt2024cystinosis—a pages 1-2)
• Regnier M et al. Worldwide disparities… (Nov 2024; survey conducted 2022; framed as “2023 perspective”). https://doi.org/10.1007/s00467-023-06179-3 (regnier2024worldwidedisparitiesin pages 1-2)
• Joseph MW et al. Gastrointestinal challenges… (Feb 2024). https://doi.org/10.1007/s00467-023-06211-6 (joseph2024gastrointestinalchallengesin pages 1-2)
• Simeoli R et al. LC‑MS/MS method for cysteamine plasma… (May 2024). https://doi.org/10.3390/ph17050649 (simeoli2024anewand pages 1-2)
• Algasem R et al. Adherence to cysteamine therapy… (Aug 2024). https://doi.org/10.3390/pharmacy12040123 (algasem2024adherencetocysteamine pages 1-2)
• Dong F et al. Gene therapy for corneal pathology... (Jul 2023). PMID:37355021; https://doi.org/10.1016/j.jtos.2023.06.002 (dong2023thegenetherapy pages 1-3)
• Bondue T et al. Evaluation of CTNS mRNA delivery... (Dec 2023). PMID:38016974; https://doi.org/10.1038/s41598-023-47085-w (bondue2023evaluationoftheefficacy pages 1-2)
• ClinicalTrials.gov: NCT03897361 (first posted 2019; primary completion 2024‑09‑18; last update 2026‑01‑14). https://clinicaltrials.gov/study/NCT03897361 (NCT03897361 chunk 1)
• ClinicalTrials.gov: NCT06027385 (GENESIS1; start 2018‑01‑15; recruitment completed 2022‑09‑30). https://clinicaltrials.gov/study/NCT06027385 (NCT06027385 chunk 1)
• ClinicalTrials.gov: NCT05843851 (start 2022‑03‑15; recruiting). https://clinicaltrials.gov/study/NCT05843851 (NCT05843851 chunk 1)

References

1. (devitt2024cystinosis—a pages 1-2): Lauren Devitt. Cystinosis — a review of disease pathogenesis, management, and future treatment options. Journal of Rare Diseases, 3:1-12, Jun 2024. URL: https://doi.org/10.1007/s44162-024-00041-2, doi:10.1007/s44162-024-00041-2. This article has 6 citations.

2. (bondue2024novelmolecularmechanisms pages 20-23): T Bondue, L van den Heuvel, R Gijsbers, and E Levtchenko. Novel molecular mechanisms and therapeutic options for renal fanconi syndrome: a focus on cystinosis. Unknown journal, 2024.

3. (cherqui2023[cystinosisfromthe pages 1-3): Stéphanie Cherqui. [cystinosis: from the gene identification to the first gene therapy clinical trial]. Medecine sciences : M/S, 39 3:253-261, Mar 2023. URL: https://doi.org/10.1051/medsci/2023025, doi:10.1051/medsci/2023025. This article has 8 citations.

4. (NCT01197378 chunk 2): Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103). Amgen. 2010. ClinicalTrials.gov Identifier: NCT01197378

5. (simeoli2024anewand pages 1-2): Raffaele Simeoli, Sara Cairoli, Marcella Greco, Francesco Bellomo, Alessandro Mancini, Chiara Rossi, Carlo Dionisi Vici, Francesco Emma, and Bianca Maria Goffredo. A new and rapid lc-ms/ms method for the determination of cysteamine plasma levels in cystinosis patients. Pharmaceuticals, 17:649, May 2024. URL: https://doi.org/10.3390/ph17050649, doi:10.3390/ph17050649. This article has 4 citations.

6. (dong2023thegenetherapy pages 1-3): Fei Dong, Hassane Amlal, Jhuwala Venkatakrishnan, Jianhua Zhang, Matthew Fry, Yong Yuan, Yu Chia Cheng, Yueh-Chiang Hu, and Winston W-Y Kao. The gene therapy for corneal pathology with novel nonsense cystinosis mouse lines created by crispr gene editing. The Ocular Surface, 29:432-443, Jul 2023. PMID:37355021; URL: https://doi.org/10.1016/j.jtos.2023.06.002, doi:10.1016/j.jtos.2023.06.002. This article has 2 citations.

7. (devitt2024ocularcystinosis–areview pages 1-2): L Devitt. Ocular cystinosis–a review of disease, diagnosis, and future treatment options. Unknown journal, 2024.

8. (heroor2024unveilingcystinosisin pages 9-11): Aniruddh Heroor, Anshuman Verma, Divya Sree Achanta, Deepak Paul Edward, and Muralidhar Ramappa. Unveiling cystinosis in india. Journal of Rare Diseases, 3:1-12, Jun 2024. URL: https://doi.org/10.1007/s44162-024-00046-x, doi:10.1007/s44162-024-00046-x. This article has 0 citations.

9. (algasem2024adherencetocysteamine pages 1-2): Reem Algasem, Nedaa Zainy, Essam Alsabban, Hamad Almojalli, Khalid Alhasan, Tariq Ali, Deiter Broering, and Hassan Aleid. Adherence to cysteamine therapy among patients diagnosed with cystinosis in saudi arabia: a prospective cohort study. Pharmacy, 12:123, Aug 2024. URL: https://doi.org/10.3390/pharmacy12040123, doi:10.3390/pharmacy12040123. This article has 0 citations.

10. (algasem2024adherencetocysteamine pages 4-6): Reem Algasem, Nedaa Zainy, Essam Alsabban, Hamad Almojalli, Khalid Alhasan, Tariq Ali, Deiter Broering, and Hassan Aleid. Adherence to cysteamine therapy among patients diagnosed with cystinosis in saudi arabia: a prospective cohort study. Pharmacy, 12:123, Aug 2024. URL: https://doi.org/10.3390/pharmacy12040123, doi:10.3390/pharmacy12040123. This article has 0 citations.

11. (algasem2024adherencetocysteamine pages 6-7): Reem Algasem, Nedaa Zainy, Essam Alsabban, Hamad Almojalli, Khalid Alhasan, Tariq Ali, Deiter Broering, and Hassan Aleid. Adherence to cysteamine therapy among patients diagnosed with cystinosis in saudi arabia: a prospective cohort study. Pharmacy, 12:123, Aug 2024. URL: https://doi.org/10.3390/pharmacy12040123, doi:10.3390/pharmacy12040123. This article has 0 citations.

12. (regnier2024worldwidedisparitiesin pages 1-2): Maitena Regnier, Sacha Flammier, Mounia Boutaba, Aliou Abdoulaye Ndongo, Aude Servais, Franz Schaefer, Elena Levtchenko, Justine Bacchetta, and Aurélia Bertholet-Thomas. Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective. Pediatric Nephrology (Berlin, Germany), 39:1113-1123, Nov 2024. URL: https://doi.org/10.1007/s00467-023-06179-3, doi:10.1007/s00467-023-06179-3. This article has 10 citations.

13. (regnier2024worldwidedisparitiesin pages 7-8): Maitena Regnier, Sacha Flammier, Mounia Boutaba, Aliou Abdoulaye Ndongo, Aude Servais, Franz Schaefer, Elena Levtchenko, Justine Bacchetta, and Aurélia Bertholet-Thomas. Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective. Pediatric Nephrology (Berlin, Germany), 39:1113-1123, Nov 2024. URL: https://doi.org/10.1007/s00467-023-06179-3, doi:10.1007/s00467-023-06179-3. This article has 10 citations.

14. (regnier2024worldwidedisparitiesin pages 2-3): Maitena Regnier, Sacha Flammier, Mounia Boutaba, Aliou Abdoulaye Ndongo, Aude Servais, Franz Schaefer, Elena Levtchenko, Justine Bacchetta, and Aurélia Bertholet-Thomas. Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective. Pediatric Nephrology (Berlin, Germany), 39:1113-1123, Nov 2024. URL: https://doi.org/10.1007/s00467-023-06179-3, doi:10.1007/s00467-023-06179-3. This article has 10 citations.

15. (regnier2024worldwidedisparitiesin media 96f6e599): Maitena Regnier, Sacha Flammier, Mounia Boutaba, Aliou Abdoulaye Ndongo, Aude Servais, Franz Schaefer, Elena Levtchenko, Justine Bacchetta, and Aurélia Bertholet-Thomas. Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective. Pediatric Nephrology (Berlin, Germany), 39:1113-1123, Nov 2024. URL: https://doi.org/10.1007/s00467-023-06179-3, doi:10.1007/s00467-023-06179-3. This article has 10 citations.

16. (NCT03897361 chunk 1): Stephanie Cherqui. Stem Cell Gene Therapy for Cystinosis. University of California, San Diego. 2019. ClinicalTrials.gov Identifier: NCT03897361

17. (NCT03897361 chunk 2): Stephanie Cherqui. Stem Cell Gene Therapy for Cystinosis. University of California, San Diego. 2019. ClinicalTrials.gov Identifier: NCT03897361

18. (NCT03897361 chunk 3): Stephanie Cherqui. Stem Cell Gene Therapy for Cystinosis. University of California, San Diego. 2019. ClinicalTrials.gov Identifier: NCT03897361

19. (NCT06027385 chunk 2): Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy. Cystinose Stiftung. 2018. ClinicalTrials.gov Identifier: NCT06027385

20. (NCT06027385 chunk 1): Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy. Cystinose Stiftung. 2018. ClinicalTrials.gov Identifier: NCT06027385

21. (NCT05843851 chunk 2): Katharina Hohenfellner,MD. Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria. Cystinose Stiftung. 2022. ClinicalTrials.gov Identifier: NCT05843851

22. (NCT05843851 chunk 1): Katharina Hohenfellner,MD. Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria. Cystinose Stiftung. 2022. ClinicalTrials.gov Identifier: NCT05843851

23. (joseph2024gastrointestinalchallengesin pages 1-2): Mark W. Joseph, Deborah R. Stein, and Adam C. Stein. Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives. Pediatric Nephrology (Berlin, Germany), 39:2845-2860, Feb 2024. URL: https://doi.org/10.1007/s00467-023-06211-6, doi:10.1007/s00467-023-06211-6. This article has 6 citations.

24. (joseph2024gastrointestinalchallengesin pages 7-9): Mark W. Joseph, Deborah R. Stein, and Adam C. Stein. Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives. Pediatric Nephrology (Berlin, Germany), 39:2845-2860, Feb 2024. URL: https://doi.org/10.1007/s00467-023-06211-6, doi:10.1007/s00467-023-06211-6. This article has 6 citations.

25. (joseph2024gastrointestinalchallengesin pages 4-6): Mark W. Joseph, Deborah R. Stein, and Adam C. Stein. Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives. Pediatric Nephrology (Berlin, Germany), 39:2845-2860, Feb 2024. URL: https://doi.org/10.1007/s00467-023-06211-6, doi:10.1007/s00467-023-06211-6. This article has 6 citations.

26. (joseph2024gastrointestinalchallengesin pages 11-13): Mark W. Joseph, Deborah R. Stein, and Adam C. Stein. Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives. Pediatric Nephrology (Berlin, Germany), 39:2845-2860, Feb 2024. URL: https://doi.org/10.1007/s00467-023-06211-6, doi:10.1007/s00467-023-06211-6. This article has 6 citations.

27. (joseph2024gastrointestinalchallengesin pages 9-10): Mark W. Joseph, Deborah R. Stein, and Adam C. Stein. Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives. Pediatric Nephrology (Berlin, Germany), 39:2845-2860, Feb 2024. URL: https://doi.org/10.1007/s00467-023-06211-6, doi:10.1007/s00467-023-06211-6. This article has 6 citations.

28. (joseph2024gastrointestinalchallengesin pages 13-14): Mark W. Joseph, Deborah R. Stein, and Adam C. Stein. Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives. Pediatric Nephrology (Berlin, Germany), 39:2845-2860, Feb 2024. URL: https://doi.org/10.1007/s00467-023-06211-6, doi:10.1007/s00467-023-06211-6. This article has 6 citations.

29. (bondue2023evaluationoftheefficacy pages 1-2): Tjessa Bondue, Sante Princiero Berlingerio, Florian Siegerist, Elena Sendino-Garvi, Maximilian Schindler, Hans Jacobus Baelde, Sara Cairoli, Bianca Maria Goffredo, Fanny Oliveira Arcolino, Jurgen Dieker, Manoe Jacoba Janssen, Nicole Endlich, Roland Brock, Rik Gijsbers, Lambertus van den Heuvel, and Elena Levtchenko. Evaluation of the efficacy of cystinosin supplementation through CTNS mRNA delivery in experimental models for cystinosis. Scientific Reports, 13:21002, Dec 2023. PMID:38016974; URL: https://doi.org/10.1038/s41598-023-47085-w, doi:10.1038/s41598-023-47085-w.